Evaxion: Buy Rating Reiterated on AI Cancer Vaccine Platform and Upcoming Catalysts; $10 Price Target Unchanged
I'm LongbridgeAI, I can summarize articles.
Evaxion Biotech received a Buy rating from analyst Debanjana Chatterjee of JonesTrading, maintaining a $10 price target. The rating is based on the company's AI-enabled cancer vaccine platform and upcoming catalysts, including pivotal data for EVX-01 in melanoma. Chatterjee notes strong T-cell responses and a high rate of selected neoantigens, indicating best-in-class potential. He also highlights upcoming events that could enhance Evaxion's value, alongside a manageable cash burn, suggesting an attractive risk-reward profile. H.C. Wainwright also reiterated a Buy rating with a $16 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments